[144] Lexeo Therapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

Form 144 notice filed for Lexeo Therapeutics, Inc. (LXEO) reporting a proposed sale of 608 shares of common stock (approximate aggregate market value $2,838.27) from restricted stock that vested on 08/15/2025. The filing shows the shares are expected to be sold on 08/18/2025 through Fidelity Brokerage Services LLC on NASDAQ. The securities were acquired by vesting as compensation from the issuer on 08/15/2025, and there are 54,001,214 shares outstanding per the filing. The filer certifies they are not aware of undisclosed material adverse information.

Positive

• Rule 144 compliance disclosure filed, showing adherence to SEC resale reporting requirements
• Transaction originates from vested restricted stock, indicating compensation rather than open-market purchase

Negative

• None.

Insights

Securities Compliance Analyst

TL;DR: Routine Rule 144 notice for a small post-vesting sale; appears procedural and non-material.

This Form 144 documents a planned sale of 608 common shares acquired via restricted stock vesting and designated as compensation. The transaction will be executed through Fidelity on NASDAQ with an indicated approximate market value of $2,838.27. Given the small size relative to the 54,001,214 shares outstanding, the filing appears to be a compliance disclosure to satisfy Rule 144 requirements rather than an event likely to affect the companys market valuation.

Equity Markets Specialist

TL;DR: Minor issuance-related sale; negligible market impact but shows insider/holder monetization of vested awards.

The notice shows restricted stock vesting on 08/15/2025 and an intended sale three days later. The aggregate value reported is small (~$2.8k) versus total outstanding shares, indicating no material dilution or liquidity effect. The declaration that no undisclosed material adverse information exists is standard. This filing is informative for transaction timing and compliance, not a material corporate development.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	608	2838.27	54001214	08/18/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/15/2025	Restricted Stock Vesting	Issuer			608	08/15/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Lexeo Therapeutics (LXEO) disclose in this Form 144?

The filing reports a proposed sale of 608 common shares valued at approximately $2,838.27, to be sold on 08/18/2025 via Fidelity on NASDAQ.

How were the shares acquired that are being sold under Rule 144?

The shares were acquired on 08/15/2025 through restricted stock vesting and were recorded as compensation.

How many Lexeo shares are outstanding according to the filing?

The filing lists 54,001,214 shares outstanding.

Does the filer report any undisclosed material information about Lexeo Therapeutics?

The filer represents by signature that they do not know any material adverse information about the issuer that has not been publicly disclosed.

Is there any report of other sales in the past three months?

The filing states "Nothing to Report" for securities sold during the past three months by the person for whose account the securities are to be sold.